Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31263636 | 0.93 | S1PR4 (0.43) | S1PR4CYP2A6NOTUMTDP1CCR1 | |
| SCHEMBL3637489 | 0.83 | CYP2A6 (0.43) | CYP2A6NOS1NR4A2DYRK1AKMO | |
| SCHEMBL4388506 | 0.81 | CYP2A6 (0.42) | S1PR4CYP2A6CCR1NOS1NR4A2 | |
| SCHEMBL10272520 | 0.81 | CYP2A6 (0.42) | S1PR4CYP2A6ABL1NOS1NR4A2 | |
| SCHEMBL14244648 | 0.79 | RECQL (0.39) | S1PR4NOTUMABL1CCR1ALDH1A1 | |
| SCHEMBL2226466 | 0.78 | ABL1 (0.44) | CYP2A6ABL1CCR1ALDH1A1NOS1 | |
| SCHEMBL30718639 | 0.78 | ABL1 (0.44) | CYP2A6ABL1CCR1ALDH1A1NOS1 | |
| SCHEMBL3642128 | 0.77 | KDM4E (0.43) | CYP2A6KDM4E | |
| SCHEMBL1999306 | 0.76 | ATM (0.51) | CYP2A6NOTUMCCR1ALDH1A1 | |
| SCHEMBL31263625 | 0.76 | NOS1 (0.40) | CYP2A6NOS1NR4A2DYRK1AKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | S1PR4 382/4885CYP2A6 359/4885NOTUM 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.